SE0001438D0 - New chemical compounds and their use in therapy - Google Patents

New chemical compounds and their use in therapy

Info

Publication number
SE0001438D0
SE0001438D0 SE0001438A SE0001438A SE0001438D0 SE 0001438 D0 SE0001438 D0 SE 0001438D0 SE 0001438 A SE0001438 A SE 0001438A SE 0001438 A SE0001438 A SE 0001438A SE 0001438 D0 SE0001438 D0 SE 0001438D0
Authority
SE
Sweden
Prior art keywords
carbon atoms
alkyl
groups
group
absent
Prior art date
Application number
SE0001438A
Other languages
English (en)
Swedish (sv)
Inventor
Durk Dijkstra De Meidoorn
Bastiaan Johan Venhuis
Haakan Vilhelm Wikstroem
Original Assignee
Axon Chemicals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Chemicals Bv filed Critical Axon Chemicals Bv
Priority to SE0001438A priority Critical patent/SE0001438D0/xx
Publication of SE0001438D0 publication Critical patent/SE0001438D0/xx
Priority to CNB018082858A priority patent/CN1234351C/zh
Priority to SI200130409T priority patent/SI1274411T1/sl
Priority to PL365113A priority patent/PL204661B1/pl
Priority to ES01922208T priority patent/ES2244604T3/es
Priority to JP2001576014A priority patent/JP4819280B2/ja
Priority to AU4898201A priority patent/AU4898201A/xx
Priority to EP01922208A priority patent/EP1274411B1/en
Priority to DK01922208T priority patent/DK1274411T3/da
Priority to AU2001248982A priority patent/AU2001248982B2/en
Priority to CNB2005101253198A priority patent/CN100383126C/zh
Priority to PCT/SE2001/000840 priority patent/WO2001078713A1/en
Priority to AT01922208T priority patent/ATE300290T1/de
Priority to CZ20023455A priority patent/CZ20023455A3/cs
Priority to CA002406044A priority patent/CA2406044C/en
Priority to US10/258,014 priority patent/US6683087B2/en
Priority to DE60112269T priority patent/DE60112269T2/de
Priority to PT01922208T priority patent/PT1274411E/pt
Priority to NZ521860A priority patent/NZ521860A/en
Priority to HU0300543A priority patent/HU229794B1/hu
Priority to ZA200207919A priority patent/ZA200207919B/xx
Priority to US10/737,782 priority patent/US6998405B2/en
Priority to HK06108406.5A priority patent/HK1088009B/xx
Priority to US11/790,465 priority patent/USRE42802E1/en
Priority to US12/945,057 priority patent/USRE43244E1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
SE0001438A 2000-04-18 2000-04-18 New chemical compounds and their use in therapy SE0001438D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0001438A SE0001438D0 (sv) 2000-04-18 2000-04-18 New chemical compounds and their use in therapy
HU0300543A HU229794B1 (hu) 2000-04-18 2001-04-17 Katekolamin prodrug fenil-etil-aminok és kondenzált gyûrûs származékaik, valamint ezek alkalmazása és ezeket tartalmazó gyógyszerkészítmények
CNB2005101253198A CN100383126C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途
AT01922208T ATE300290T1 (de) 2000-04-18 2001-04-17 Phenylethylamine und ringkondensierte varianten als pro-drugs von katecholaminen sowie ihre verwendung
PL365113A PL204661B1 (pl) 2000-04-18 2001-04-17 Fenyloetyloaminy i odmiany skondensowanych układów pierścieniowych jako proleki katecholamin, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
ES01922208T ES2244604T3 (es) 2000-04-18 2001-04-17 Feniletilaminas y variantes de anillos condensados como profarmacos de catecolaminas y su uso.
JP2001576014A JP4819280B2 (ja) 2000-04-18 2001-04-17 カテコールアミンのプロドラッグとしてのフェニルエチルアミンおよび縮合環のヴァリアント（ｖａｒｉａｎｔ）、ならびにその使用
AU4898201A AU4898201A (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
EP01922208A EP1274411B1 (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
DK01922208T DK1274411T3 (da) 2000-04-18 2001-04-17 Phenylethylaminer og ringkondenserede varianter som prodrugs af catecholaminer og deres anvendelse
AU2001248982A AU2001248982B2 (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
CNB018082858A CN1234351C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途
PCT/SE2001/000840 WO2001078713A1 (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
SI200130409T SI1274411T1 (sl) 2000-04-18 2001-04-17 Feniletilamini in variante s kondenziranimi obroci kot predzdravila kateholaminov in njihova uporaba
CZ20023455A CZ20023455A3 (cs) 2000-04-18 2001-04-17 Fenylethylaminy a jejich varianty s anelovanými kruhy jako proléčiva katecholaminů a jejich použití
CA002406044A CA2406044C (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
US10/258,014 US6683087B2 (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
DE60112269T DE60112269T2 (de) 2000-04-18 2001-04-17 Phenylethylamine und ringkondensierte varianten als pro-drugs von katecholaminen sowie ihre verwendung
PT01922208T PT1274411E (pt) 2000-04-18 2001-04-17 Feniletilaminas e variantes de aneis condensados como pro-farmacos de catecolaminas, e sua utilizacao
NZ521860A NZ521860A (en) 2000-04-18 2001-04-17 Phenylethylamines and condensed rings variants as drugs of catecholamines, preparation process and their use
ZA200207919A ZA200207919B (en) 2000-04-18 2002-10-02 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use.
US10/737,782 US6998405B2 (en) 2000-04-18 2003-12-18 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
HK06108406.5A HK1088009B (en) 2000-04-18 2006-07-28 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
US11/790,465 USRE42802E1 (en) 2000-04-18 2007-04-25 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
US12/945,057 USRE43244E1 (en) 2000-04-18 2010-11-12 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0001438A SE0001438D0 (sv) 2000-04-18 2000-04-18 New chemical compounds and their use in therapy

Publications (1)

Publication Number Publication Date
SE0001438D0 true SE0001438D0 (sv) 2000-04-18

Family

ID=20279367

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0001438A SE0001438D0 (sv) 2000-04-18 2000-04-18 New chemical compounds and their use in therapy

Country Status (19)

Country Link
US (4) US6683087B2 (cg-RX-API-DMAC7.html)
EP (1) EP1274411B1 (cg-RX-API-DMAC7.html)
JP (1) JP4819280B2 (cg-RX-API-DMAC7.html)
CN (2) CN100383126C (cg-RX-API-DMAC7.html)
AT (1) ATE300290T1 (cg-RX-API-DMAC7.html)
AU (2) AU4898201A (cg-RX-API-DMAC7.html)
CA (1) CA2406044C (cg-RX-API-DMAC7.html)
CZ (1) CZ20023455A3 (cg-RX-API-DMAC7.html)
DE (1) DE60112269T2 (cg-RX-API-DMAC7.html)
DK (1) DK1274411T3 (cg-RX-API-DMAC7.html)
ES (1) ES2244604T3 (cg-RX-API-DMAC7.html)
HU (1) HU229794B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ521860A (cg-RX-API-DMAC7.html)
PL (1) PL204661B1 (cg-RX-API-DMAC7.html)
PT (1) PT1274411E (cg-RX-API-DMAC7.html)
SE (1) SE0001438D0 (cg-RX-API-DMAC7.html)
SI (1) SI1274411T1 (cg-RX-API-DMAC7.html)
WO (1) WO2001078713A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207919B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616028A1 (en) * 2005-07-22 2007-02-01 Sloan-Kettering Institute For Cancer Research Synthesis of scabronines and analogues thereof
US7910623B2 (en) * 2005-07-22 2011-03-22 Sloan-Kettering Institute For Cancer Research Synthesis of scabronines and analogues thereof
AR058439A1 (es) 2005-07-26 2008-02-06 Portela & Ca Sa Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
CA2678391C (en) 2007-01-31 2017-01-17 David Alexander Learmonth Dosage regimen for comt inhibitors
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
MX2010009610A (es) 2008-03-17 2010-09-30 Bial Portela & Ca Sa Formas de cristal de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3 -il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol.
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
BRPI1014865B1 (pt) 2009-04-01 2020-03-17 Bial - Portela & C.A., S.A. Composição que compreende grânulos compreendendo 2,5- dicloro- 3- (5- (3,4- dihidróxi- 5- nitrofenil)- 1,2,4- oxadiazol- 3- il)- 4,6- dimetilpiridina 1- óxido e formulação farmacêutica
US8492538B1 (en) * 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
WO2011034217A1 (ja) * 2009-09-18 2011-03-24 株式会社Ｒｉｖｅｒｓｏｎ ポリフェノール誘導体及びそれの産生方法
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
RS59666B1 (sr) 2011-12-13 2020-01-31 BIAL PORTELA & Cª S A Hemijsko jedinjenje korisno kao intermedijer za pripremu inhibitora katehol-o-metiltransferaze
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
CN119707810A (zh) 2019-05-21 2025-03-28 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP7696829B2 (ja) 2019-05-21 2025-06-23 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ
EP4247793A1 (en) 2020-11-17 2023-09-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
CA3249364A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NEW ESTERS OF COMPOUNDS 1, 2, 3, 4, 4A, 5, 6, 7, 8, 9, 10, 10A-DODECAHYDROBENZO [G]QUINOLIN-6-OL AND THEIR USES
AU2023259559A1 (en) 2022-04-25 2024-10-31 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078571A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL CARBONATES AND CARBAMATES OF 1,2,3,4,4a,5,6,7,8,9,10,10a- DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078574A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1179954A (fr) * 1956-02-11 1959-05-29 Rhone Poulenc Sa -1 cyclohexène-1 ones-3 nu-disubstituées, leurs dérivés et leur préparation
US3991207A (en) * 1971-03-18 1976-11-09 Pfizer Inc. Combination therapy for Parkinson's disease
GB1593888A (en) * 1977-12-22 1981-07-22 Wyeth John & Brother Ltd Hexahydroazepine piperidine and pyrrolidine derivatives
ZA805648B (en) * 1979-09-14 1982-04-28 Sandoz Ltd Tetraline derivatives, their production and pharmaceutical compositions containing them
EP0026848B1 (de) * 1979-09-14 1983-05-04 Sandoz Ag Tetralinderivate, ihre Herstellung und Heilmittel, welche diese Verbindungen enthalten
EP0077754B1 (en) * 1981-10-16 1990-09-26 Sandoz Ag Novel pharmaceutically active 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)quinoline derivatives
EP0463119A4 (en) 1989-07-05 1992-01-22 Whitby Research Incorporated Substituted 2-aminotetralins
ES2157204T3 (es) 1991-04-17 2001-08-16 Upjohn Co Derivados de (s)-3-fenilpiperidina sustituidos, su preparacion y uso como antagonistas de autorreceptores de dopamina.
DE4114325A1 (de) 1991-05-02 1992-11-05 Sandoz Ag Octahydrobenzo(g)chinolin, seine herstellung und verwendung
GB2260980A (en) * 1991-10-31 1993-05-05 Shell Int Research Preparation of unsaturated cyclic ketones
GB9326010D0 (en) * 1993-12-21 1994-02-23 Sandoz Ltd Improvements in or relating to organic compounds
CN1182103C (zh) * 1997-08-07 2004-12-29 株式会社富吉摩托普拉泽兹 乙胺衍生物
US6187808B1 (en) 1998-07-28 2001-02-13 Warner-Lambert Company Hexahydro-naphthalenone oximes and hydrazones
SV2001000202A (es) * 1999-10-20 2001-10-16 Warner Lambert Co Uso de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina para el tratamiento del mal de parkinson

Also Published As

Publication number Publication date
US20030087948A1 (en) 2003-05-08
NZ521860A (en) 2004-03-26
EP1274411B1 (en) 2005-07-27
US6998405B2 (en) 2006-02-14
ES2244604T3 (es) 2005-12-16
JP4819280B2 (ja) 2011-11-24
ATE300290T1 (de) 2005-08-15
CN1234351C (zh) 2006-01-04
HU229794B1 (hu) 2014-07-28
AU4898201A (en) 2001-10-30
SI1274411T1 (sl) 2005-12-31
USRE42802E1 (en) 2011-10-04
HUP0300543A3 (en) 2009-04-28
WO2001078713A1 (en) 2001-10-25
CN100383126C (zh) 2008-04-23
CA2406044A1 (en) 2001-10-25
US6683087B2 (en) 2004-01-27
CZ20023455A3 (cs) 2003-04-16
PT1274411E (pt) 2005-11-30
ZA200207919B (en) 2003-10-02
CN1781910A (zh) 2006-06-07
HUP0300543A2 (hu) 2003-07-28
PL204661B1 (pl) 2010-01-29
AU2001248982B2 (en) 2005-12-15
USRE43244E1 (en) 2012-03-13
DK1274411T3 (da) 2005-11-14
CN1450894A (zh) 2003-10-22
DE60112269T2 (de) 2006-05-24
HK1088009A1 (en) 2006-10-27
US20040138281A1 (en) 2004-07-15
DE60112269D1 (de) 2005-09-01
JP2004500426A (ja) 2004-01-08
CA2406044C (en) 2009-10-27
EP1274411A1 (en) 2003-01-15
PL365113A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
SE0001438D0 (sv) New chemical compounds and their use in therapy
BG107120A (bg) Нови бавнодействащи бетамиметици, метод за тяхното получаване и приложението им като лекарствени средства
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0004040A1 (hu) Antimikrobiális hatású pleuromutilinszármazékok, eljárás ezek előállítására, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
WO2003064404A1 (en) 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
ATE313535T1 (de) Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung
HUP0302167A2 (hu) Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
AR029821A1 (es) Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento
TW200621772A (en) Compounds which increase apolipoprotein a-1 production and uses thereof in medicine
DE602004005323D1 (de) Azidfreies verfahren zur herstellung von 1,2-diaminoverbindungen
WO2004089308A3 (en) Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
JO2616B1 (ar) مركبات ثلاثية الحلقات جديدة، طريقة من أجل تحضيرها ومركباتها الصيدلانية
CA2486872A1 (en) Nf-kb inhibitors and uses thereof
NZ519126A (en) Novel IL-8 receptor antagonists
TW200811100A (en) Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
NZ520155A (en) Thienopyridine derivatives, their production and use
JP2010505759A5 (cg-RX-API-DMAC7.html)
JP4030578B2 (ja) 新規の抗痙攣作用を有する４位に二置換アミン基を有する１−アリール（アラルキル）−イミダゾリン−２−オンおよびその製法
JP2004502773A5 (cg-RX-API-DMAC7.html)
PL97347B1 (pl) Sposob wytwarzania nowych 2-fenylohydrazyno-tiazolin lub-tiazyn
PT96536A (pt) Processo para a preparacao duma composicao fungicida contendo esteres de acido 2-{6-(pirimidinil)-indol-1-il}-acrilico substituidos e de produtos intermediarios
WO1998049165B1 (en) CYTOTOXIC COMPOUNDS: DERIVATIVES OF THE PYRIDO[2,3,4-kl] ACRIDINE RING SYSTEM
Yu et al. TARGET SYNTHESIS OF NOVEL PHARMACOLOGICAL ACTIVE MONO-AND BICYCLIC PIPERIDINES
TH64995A (th) ซับสทิทิวเทดพิเพอริดีนชนิดใหม่, สารผสมทางเภสัชกรรมที่มีสารประกอบเหล่านี้, การใช้สารประกอบเหล่านี้และกรรมวิธีสำหรับเตรียมสารประกอบเหล่านี้
TH72849A (th) สารยับยั้งฟาร์เนซิลโปรตีนทรานส์เฟอเรสชนิดใหม่เป็นยาต้านมะเร็ง